<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753480</url>
  </required_header>
  <id_info>
    <org_study_id>DMU4506g</org_study_id>
    <nct_id>NCT00753480</nct_id>
  </id_info>
  <brief_title>A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of D4064A Administered Intravenously to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer After a Platinum-Containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase I, multicenter, open-label, dose-escalation study of single-agent D4064A&#xD;
      administered by IV infusion to patients with recurrent or persistent epithelial ovarian&#xD;
      cancer (EOC), primary peritoneal cancer (PPC), and fallopian tube cancer (FTC) who have&#xD;
      previously received a platinum-containing regimen. The study will enroll up to 56 patients at&#xD;
      up to six investigative sites in the United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>September 2008</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Length of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature, and severity of adverse events</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-D4064A antibodies</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs and clinical laboratory results</measure>
    <time_frame>Length of study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D4064A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Advanced, histologically documented epithelial ovarian, primary peritoneal, or&#xD;
             fallopian tube cancer that has progressed or relapsed during or within 12 months of&#xD;
             treatment with a platinum-containing chemotherapy regimen, and for which no standard&#xD;
             therapy exists&#xD;
&#xD;
          -  History of receiving five or fewer prior chemotherapy-containing regimens for EOC,&#xD;
             PPC, or FTC (including primary therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with chemotherapy or experimental anti-cancer agents within 4 weeks&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Prior treatment with oregovomab (OvaRex(R)) or abagovomab&#xD;
&#xD;
          -  History or clinical evidence of central nervous system or brain metastases&#xD;
&#xD;
          -  Grade â‰¥ 2 peripheral neuropathy&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or&#xD;
             murine monoclonal antibodies&#xD;
&#xD;
          -  History of clinically symptomatic liver disease, including viral or other hepatitis,&#xD;
             history of or current alcoholism, or cirrhosis&#xD;
&#xD;
          -  Untreated or persistent/recurrent malignancy (other than EOC, PPC, or FTC)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Holden, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>November 6, 2008</last_update_submitted>
  <last_update_submitted_qc>November 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Clinical Trials Posting Group</name_title>
    <organization>Genentech, Inc.</organization>
  </responsible_party>
  <keyword>EOC</keyword>
  <keyword>PPC</keyword>
  <keyword>FTC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

